My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Nebivolol (R 065824)
    Nebivolol (R 065824)

    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V1112
    CAS #: 118457-14-0Purity ≥98%

    Description: Nebivolol (R065824; R-065824; Nobiten; Vasoxen) is a potent and selective beta1/β1-adrenoceptor antagonist with antihypertensive effects. It inhibits β1-adrenoceptor with an IC50 of 0.8 nM. As a beta blocker, nebivolol has been used to treat high blood pressure and heart failure. 

    References: Mol Pharmacol. 1988 Dec;34(6):843-51; Circ J. 2008 Apr;72(4):660-70.

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)441.9 
    CAS No.152520-56-4 
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 88 mg/mL (199.1 mM) 
    Water: <1 mg/mL
    Ethanol: <1 mg/mL
    Other info

    Chemical Name: 1-((R)-6-fluorochroman-2-yl)-2-(((R)-2-((R)-6-fluorochroman-2-yl)-2-hydroxyethyl)amino)ethanol


    InChi Code: InChI=1S/C22H25F2NO4/c23-15-3-7-19-13(9-15)1-5-21(28-19)17(26)11-25-12-18(27)22-6-2-14-10-16(24)4-8-20(14)29-22/h3-4,7-10,17-18,21-22,25-27H,1-2,5-6,11-12H2/t17-,18?,21-,22-/m1/s1

    SMILES Code: O[[email protected]](CNCC([[email protected]]1CCC2=CC(F)=CC=C2O1)O)[[email protected]]3CCC4=CC(F)=CC=C4O3

    SynonymsR-65824; Nebivolol; R 065824; R065824; Nobiten; Vasoxen

    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      • V1
      • C2
      • V2
    In Vitro

    In vitro activity: Nebivolol shows high affinity and selectivity for beta 1-adrenergic receptor sites in a rabbit lung membrane preparation (Ki value = 0.9 nM and beta 2/beta 1 ratio = 50). Nebivolol displays β1-adrenoceptor selectivity with the Ki(β2)/Ki(β1) value of 40.7 judged by competition experiments to 3H-CGP 12.1777 in the presence of CGP 207.12 A (300 nM, Kiβ2) or ICI 118.551 (50 nM, Kiβ1). Nebivolol reduces cell proliferation of human coronary smooth muscle cells (haCSMCs) and endothelial cells (haECs) in a concentration- and time-dependent maner. Nebivolol treatment for 7 days causes significant reduction in cell growth of haCSMCs with IC50 of 6.1 μM, and inhibits accelerated haCSMC proliferation stimulated by growth factors PDGF-BB, bFGF, and TGFβ with IC50 values of 6.8 μM, 6.4 μM and 7.7 μM, repectively. Nebivolol treatment (10-5 M) of haCSMCs for 48 hours induces a moderate apoptosis of 23% and a decrease from 16% to 5% in the number of cells in S-phase. During Nebivolol incubation, NO formation of HaCEs increases, while endothelin-1 transcription and secretion are suppressed.

    Cell Assay: Cells [Human coronary smooth muscle cells (haCSMCs) and endothelial cells (haECs)] are exposed to different concentrations of Nebivolol (10-7~10-5 M) for 1, 2, 4, 7 and 14 days. Cell proliferation is analyzed by bromodeoxyuridine (BrdU) incorporation, and cell apoptosis is detected by PI or annexin V staining.

    In VivoAdministratiion of Nebivolol (initially by iv within 10 minutes of reperfusion and then orally) to rats with myocardial infarction (MI) reduces myocardial apoptosis, which is mediated by regulation of NO . Nebivolol, significantly, prevents left ventricular (LV) pressure changes, reduces total and regional apoptotic cardiomyocytes. Nebivolol treatment lowers mean blood pressure (MBP) in rats with MI slightly, but not significantly. 
    Animal modelMale Sprague Dawley rat myocardial infarction (MI) model 
    Formulation & DosageDissolved in DMSO and diluted in saline; 2.0 mg/kg; Gastric gavage once daily 

    Mol Pharmacol. 1988 Dec;34(6):843-51; Circ J. 2008 Apr;72(4):660-70. 

    These protocols are for reference only. InvivoChem does not independently validate these methods.

    Effects of nebivolol on left ventricular fibrosis and heart function after MI. PLoS One. 2014; 9(5): e98179.
    Nebivolol administration decreased cardiomyocyte apoptosis. PLoS One. 2014; 9(5): e98179.
    Nebivolol administration altered the phosphorylation status of eNOS and increased the expression of nNOS. PLoS One. 2014; 9(5): e98179.


      Home Prev Next Last page / pices


      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      Do you confirm the receipt?